ARA290, also written ARA-290 and named cibinetide, is an 11-residue peptide. The supplied report writes its sequence as pGlu-EQLERALNSS: the N-terminal pyroglutamate is part of the molecular description.
ARA290 names and sequence
The supplied ARA290 report names cibinetide and prints pGlu-EQLERALNSS. The design paper distinguishes HBSP from its N-terminal pyroglutamate form, pHBSP, and provides the structural relationship behind that naming.Supplied ARA290 10 mg report — lot ARA-41-8WX (opens in a new tab)Brines et al. (2008) (opens in a new tab)
| Field | Documented detail |
|---|---|
| Names | ARA290; ARA-290; cibinetide |
| Structural description | pHBSP: pyroglutamate helix B surface peptide |
| Sequence | pGlu–Glu–Gln–Leu–Glu–Arg–Ala–Leu–Asn–Ser–Ser (pGlu-EQLERALNSS) |
| Residue count | 11, including the N-terminal pGlu residue |
| CAS number | 1208243-50-8 (PubChem registry number for cibinetide, ARA290). The supplied report does not print a CAS number. |
| Molecular formula and molecular weight | Not established by the cited identity passages or supplied report |
A surface-derived sequence is not a continuous fragment
Brines and colleagues constructed the 11-residue sequence from spatially adjacent residues on the exposed helix B surface of erythropoietin. Those positions are not a single continuous interval of the parent’s primary sequence. The design relationship is therefore three-dimensional as well as sequence-based.Brines et al. (2008) (opens in a new tab)
Keep the pGlu form separate from a version with a different N-terminal residue. Removing the prefix from a specification loses the very terminal distinction recorded in the design paper and the supplied report.Brines et al. (2008) (opens in a new tab)Supplied ARA290 10 mg report — lot ARA-41-8WX (opens in a new tab)
Connect the reference to the supplied material
The supplied report describes a synthetic freeze-dried 11-residue material and records LC-HRMS identity against a qualified reference. Content and related substances are assessed separately. Match the sequence, name and lot ARA-41-8WX before comparing its chromatographic percentage with another report.Supplied ARA290 10 mg report — lot ARA-41-8WX (opens in a new tab)
The report does not disclose a complete salt or hydrate specification. Keep the printed peptide identity and the separate water and residual-TFA measurements visible, rather than supplying an unverified formula for the whole powder.Supplied ARA290 10 mg report — lot ARA-41-8WX (opens in a new tab)
Product and certificate documents
Sources and further detail
- Brines et al. (2008) (opens in a new tab)
Existing dossier design and sequence passages: spatial surface relationship, HBSP/pHBSP distinction and terminal pyroglutamate only.
- Supplied ARA290 10 mg report — lot ARA-41-8WX (opens in a new tab)
Supplied report: identity wording and analytical fields. Results concern the named sample and lot; this is document transcription, not independent authentication.
Identity sources and supplied documents checked for this revision on 3 October 2026. Report transcription is separate from independent authentication. This article has not undergone independent scientific peer review.